Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Hallgren

Gastroenterology Louisville, CO Doctor of Osteopathy

NPI 1205929841 CMS profile 327198

80 Health Park Dr Ste 270, Louisville, CO 80027

Open in the dashboard

General payments

$5,705

389 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Hallgren of Louisville, CO is reported in the CMS Open Payments database as having received $5,705 across 389 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $861 41
2024 General $556 36
2023 General $1,011 67
2022 General $1,370 105
2021 General $1,005 74
2020 General $277 16
2019 General $625 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Hallgren
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Scott Hallgren were reported at $861. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Scott Hallgren Gastroenterology median Middle half National median
2019 $625 $417 $126–$1,100 $163
2020 $277 $224 $74–$624 $114
2021 $1,005 $352 $106–$1,054 $132
2022 $1,370 $448 $129–$1,270 $149
2023 $1,011 $533 $150–$1,390 $160
2024 $556 $605 $160–$1,606 $164
2025 $861 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,317 188 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $567 43 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $386 24 payments
  4. Gilead Sciences, Inc. $300 17 payments
  5. Janssen Biotech, Inc. $263 12 payments
  6. Pfizer Inc. $214 12 payments
  7. Merck Sharp & Dohme Corporation $189 13 payments
  8. Celgene Corporation $156 11 payments
  9. Braintree Laboratories, Inc. $127 7 payments
  10. Regeneron Healthcare Solutions, Inc. $120 6 payments
  11. Other $1,065 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,705 389 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $540 43 payments
  2. CREON $530 50 payments
  3. RINVOQ $524 43 payments
  4. LINZESS $505 36 payments
  5. XIFAXAN $413 31 payments
  6. SKYRIZI Immunology $345 34 payments
  7. STELARA $232 11 payments
  8. MAVYRET $226 17 payments
  9. XELJANZ $214 12 payments
  10. SKYRIZI Immunology $214 11 payments
  11. Other $2,911 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

929

Median for Gastroenterology: 569

Drug cost

$67,244

Median for Gastroenterology: $104,976

Branded share of claims

29.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 11 $18,383
Linzess Linaclotide Brand 17 $15,116
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 176 $11,810
Pantoprazole Sodium Generic 388 $5,208
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 17 $2,796
Colestipol Hcl Generic 20 $2,224
Omeprazole Generic 107 $2,222
Budesonide Dr Budesonide Brand 24 $2,104
Cholestyramine Cholestyramine (With Sugar) Brand 17 $1,957
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 16 $1,917

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$57,358

Medicare's payments for the services billed

Medicare patients

276

Average age 72

Services billed

505

133 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 47%
Ischemic heart disease 29%
Depression 20%
Cancer 17%
Osteoporosis 16%
Diabetes 15%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$55 — —
OMVOH
$52 — —
LINZESS
$45 17 —
DUPIXENT
$44 — —
RINVOQ
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record